So, accumulating at current levels will not make sense. Exit and accept the loss. Mankind Pharma (₹2,518.40): The long-term trend is up. Within that, the stock is in a corrective fall.

Jan 23 (Reuters) - India's Mankind Pharma (MNKI.NS), opens new tab reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses. Manforce condom and Prega ...

Mankind Pharma has undergone a significant correction from its Rs 3,054 peak, briefly dipping below Rs 2,400. The stock found strong support near its previous swing low, aligning with the 200 DEMA ...

Shares of Mankind Pharma slipped 4 percent to Rs 2,606, snapping its two-day gaining streak on the bourses on January 21 after Macquarie downgraded Mankind Pharma to "Underperform" with a target ...

New Delhi: Drugmaker, Mankind Pharma, has announced the sale of its entire stake in Mahananda Spa and Resorts Private Limited, a Wholly Owned Subsidiary Company to Chalet Hotels Limited for an ...

Rajeev Juneja, managing director of Mankind Pharma, discusses the company's plans to collaborate with celebrities like Deepika Padukone and Alia Bhatt for advertisements. He praises Anushka Sharma ...

UTI-Low Duration Fund (IDCW-Q) 33.14 35,00,00,000 0.99 UTI-Low Duration Fund (IDCW-A) 33.14 35,00,00,000 0.99 UTI-Low Duration Fund (Bonus) 33.14 35,00,00,000 0.99 ...

Mankind Pharma Ltd and Innovent Biologics on Thursday announced a partnership to exclusively license and commercialise innovative immunotherapy drug Sintilimab, used in the treatment of cancer, in the ...

Mankind Pharma Ltd., incorporated in the year 1991, is a Small Cap company (having a market cap of Rs 98,782.96 Crore) operating in Pharmaceuticals sector. Mankind Pharma Ltd. key Products/Revenue ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Mankind Pharma Ltd share price previously? Mankind Pharma Ltd share price was down by -1.13% from the previous ...

Short Term Investments 3,004.49 1,216.79 888.40 1,316.49 ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.